THE POTENTIAL ROLE OF EPSTEIN BARR VIRUS IN MULTIPLE SCLEROSIS MOLECULAR AND SEROLOGICAL STUDY

Abstract

The aim: To identify the relation between EBV infection/reactivation and multiple sclerosis, compared to the normal controls. Materials and methods: A case-control study conducted in 120 MS patients, aged between 12-42 years, and 120 apparently healthy age- and sex-matched volunteers as controls. Viral DNA was extracted from 100μl of plasma samples, and then viral DNA was detected and quantified by quantitative real time-polymerase chain reaction (q-PCR). Serum samples were used for the detection of anti-EBNA-1 IgG. Results: Quantitative polymerase chain reaction of EBV showed absence of EBV viremia in all MS patients and control. However, anti EBNA-1 IgG antibody was positive in 51.7% (62/120) of MS patients and 39.2% (47/120) of controls, (P=0.035). The median of anti EBNA-1 IgG level in MS patients and controls were 81.08 U/ml and 67.73 U/ml, respectively (P=0.043). Additionally, EBNA-1 antibody was significantly higher in younger age groups. Patients with the first-line and second-line treatment showed no significant differences in anti EBNA-1 IgG levels, while the median level in patients without treatment (newly diagnosed) was higher. Conclusions: EBNA-1antibody could play a significant role in development of MS, as it is significantly higher in MS patients than in controls, especially at younger age groups, at early stages of the disease and in female patients.